Gorlick R, Janeway K, Lessnick S, Randall RL, Marina N, Committee on behalf of the COGBT. Children's Oncology Group's 2013 blueprint for research: Bone tumors. Pediatr Blood Cancer. 2013;60:1009-15.

Smith MA, Seibel NL, Altekruse SF, Ries LAG, Melbert DL, O'Leary M, et al. Outcomes for Children and Adolescents With Cancer: Challenges for the Twenty-First Century. J Clin Oncol. 2010;28:2625-34.

Crompton BD, Stewart C, Taylor-Weiner A, Alexe G, Kurek KC, Calicchio ML, et al. The Genomic Landscape of Pediatric Ewing Sarcoma. Cancer Discov. 2014;4:1326-41.

Nature. 1992;359:162-5.

May WA, Lessnick SL, Braun BS, Klemsz M, Lewis BC, Lunsford LB, et al. The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI-1. Mol Cell Biol. 1993;13:7393-8.

Tirode F, Surdez D, Ma X, Parker M, Le Deley MC, Bahrami A, et al. Genomic Landscape of Ewing Sarcoma Defines an Aggressive Subtype with Co-Association of STAG2 and TP53 Mutations. Cancer Discov. 2014;4:1342-53.

Brohl AS, Solomon DA, Chang W, Wang J, Song Y, Sindiri S, et al. The Genomic Landscape of the Ewing Sarcoma Family of Tumors Reveals Recurrent STAG2 Mutation.

PLoS Genet. 2014;10:e1004475.

Lerman DM, Monument MJ, McIlvaine E, Liu X, Huang D, Monovich L, et al. Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2015;62:759-65.

Factors Affecting EWS-FLI1 Activity in Ewing's Sarcoma. Sarcoma. 2011;2011:352580.